|
Global pharma major Lupin Limited (Lupin) announced the successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) at its Pithampur facilities in India. The inspection was conducted from 20th March to 24th March, 2023.
“We are proud that our Pithampur site has been successfully inspected by the MHRA again, highlighting our unwavering commitment to quality and compliance. With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility and maintaining the highest standards of quality and compliance is a must,” said Nilesh Gupta, managing director, Lupin.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
|